Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

11.5K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.5K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

718
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
718
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

905
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
905
Subviral Agents01:29

Subviral Agents

437
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
437
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

1.4K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multifunctional Nanoparticles for Theranostics of Protein Misfolding Diseases: A Systematic Review.

Journal of biomedical materials research. Part B, Applied biomaterials·2026
Same author

Gpnmb defines a phagocytic state of microglia linked to cell death in prion disease mouse model.

Nature communications·2026
Same author

Chrysoeriol-Mediated Neuroprotection in Parkinson's Disease in Mice: Targeting Apoptosis, α-Synuclein Accumulation, and Functional Recovery.

The Yale journal of biology and medicine·2026
Same author

Reduced plasma TIA-1: bridging established pathology and novel biomarker potential.

Alzheimer's research & therapy·2026
Same author

Domain-adapted discovery of PET depolymerisation routes using in-house curated scientific literature.

Chemical communications (Cambridge, England)·2026
Same author

A distinct tau oligomer strain defines the molecular and proteomic landscape of rapidly progressive Alzheimer's disease.

Acta neuropathologica·2026

Related Experiment Video

Updated: Jan 3, 2026

Prion Safety Laboratory Swipe Test
06:01

Prion Safety Laboratory Swipe Test

Published on: February 14, 2025

1.2K

Therapies for prion diseases.

Saima Zafar1, Aneeqa Noor2, Inga Zerr2

  • 1Clinical Dementia Center and German Center for Neurodegenerative Diseases, Department of Neurology, Georg-August University, University Medical Center Göttingen, Göttingen, Germany; Biomedical Engineering and Sciences Department, School of Mechanical and Manufacturing Engineering, National University of Sciences and Technology, Islamabad, Pakistan.

Handbook of Clinical Neurology
|November 16, 2019
PubMed
Summary

Therapeutic trials for Creutzfeldt-Jakob disease (CJD) are becoming feasible due to advances in molecular biology and diagnostics. Addressing challenges like disease rarity and varied presentation is crucial for future drug efficacy evaluation in CJD patients.

Keywords:
Disease heterogeneityPrP(Sc)PrionSurvivalTherapy

More Related Videos

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

11.0K
Protein Misfolding Cyclic Amplification of Prions
10:12

Protein Misfolding Cyclic Amplification of Prions

Published on: November 7, 2012

20.0K

Related Experiment Videos

Last Updated: Jan 3, 2026

Prion Safety Laboratory Swipe Test
06:01

Prion Safety Laboratory Swipe Test

Published on: February 14, 2025

1.2K
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

11.0K
Protein Misfolding Cyclic Amplification of Prions
10:12

Protein Misfolding Cyclic Amplification of Prions

Published on: November 7, 2012

20.0K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Clinical Medicine

Background:

  • Recent progress in understanding prion disease molecular biology.
  • Enhancements in clinical diagnostic techniques for prion diseases.
  • Past therapeutic attempts for Creutzfeldt-Jakob disease (CJD) have been limited, with few controlled trials.

Purpose of the Study:

  • To explore the feasibility of therapeutic trials in Creutzfeldt-Jakob disease (CJD) patients.
  • To identify and address challenges in evaluating drug efficacy for CJD.

Main Methods:

  • Review of recent advances in prion disease research.
  • Analysis of past therapeutic interventions and trial methodologies.
  • Identification of specific challenges in CJD clinical trials.

Main Results:

  • Clinical trials for CJD are demonstrated to be feasible.
  • Several compounds have been tested in case reports and patient series, but controlled trials remain rare.
  • Specific challenges include disease rarity, lack of preclinical tests, and heterogeneous clinical presentation.

Conclusions:

  • Advances in molecular biology and diagnostics support the consideration of therapeutic trials in CJD.
  • Overcoming challenges such as disease rarity and clinical heterogeneity is essential for successful drug evaluation.
  • Future research must carefully address these specific problems to advance CJD therapeutics.